MNK Recent Acquisitions
At Mallinckrodt Pharmaceuticals, we continually look for companies and products that align with our strategic vision – to be an innovation-driven specialty pharmaceutical company focused on improving outcomes for patients with severe and critical conditions. Our acquisitions help enhance and expand our diverse product portfolio and growing pipeline. We invest in our areas of focus that include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; and analgesics.
To see some of the companies we have acquired along the way, select from the growing list below.
Sucampo